In 2021, Gongdong Medical achieved operating income of CNY 1.194 billion, a year-on-year increase of 43.95%; net profit attributable to the parent company of CNY 311 million, a year-on-year increase of 37.68%; deducted non-net profit of CNY 296 million, a year-on-year increase of 37.68%; net cash flow from operating activities is CNY 373 million, a year-on-year increase of 54.01%; during the reporting period, Gongdong Medical's basic earnings per share was CNY 2.77, and the weighted average return on equity was 24.66%. The company's 2021 distribution plan is: It plans to distribute CNY 13.8 (tax included) for every 10 shares to all shareholders.

During the reporting period, the company's total R&D investment was CNY 58.2906 million, accounting for 4.88% of operating income. The total investment and the proportion of operating income increased by 57.62% and 0.42 percentage points respectively over the same period of the previous year.

In the first quarter of 2022, the company achieved operating income of about CNY 348 million, a year-on-year increase of 32.71%. The net profit attributable to shareholders of the listed company was CNY 95.0543 million, a year-on-year increase of 19.77%.In the first quarter of 2022, the company achieved operating income of about CNY 348 million, a year-on-year increase of 32.71%. The net profit attributable to shareholders of the listed company was CNY 95.0543 million, a year-on-year increase of 19.77%.